We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Beam Measurement Approach Could Support More Precise Ion Therapy

By HospiMedica International staff writers
Posted on 15 Oct 2026

Ion beam therapy uses accelerated atomic nuclei to damage cancer cells while limiting exposure to surrounding tissue. More...

However, organ motion can shift where the beam deposits most of its energy by a few millimeters. Clinicians therefore irradiate a small safety margin around the tumor, which can expose nearby sensitive organs. Researchers have now developed a noninvasive method to measure mixed ion beams during irradiation.

TU Wien and MedAustron (Wiener Neustadt, Austria) have identified a way to determine the ratio of carbon and helium ions in a mixed beam without stopping or disturbing it. Such beams combine carbon nuclei, which destroy tumor tissue, with helium nuclei that help monitor patient anatomy during treatment. To clear the beam for irradiation, however, its carbon-to-helium ratio must first be known precisely.

The two ion species can be accelerated together because their charge-to-mass ratios are nearly identical after all electrons have been removed. This similarity allows them to follow almost the same trajectory in a synchrotron. Their behavior differs once they enter tissue: helium ions travel approximately three times farther than carbon ions and can emerge from the body for measurement.

Measuring the residual energy of these emerging helium ions allows the penetration depth of the carbon ions to be reconstructed, helping determine whether irradiation is proceeding as planned. This monitoring capability could also support smaller safety margins around tumors near sensitive organs, provided that the beam composition matches the desired ratio.

To determine that composition, the new measurement method exploits a small physical difference between the otherwise closely matched ion species. A carbon nucleus has about 0.065% less than three times the mass of a helium nucleus, causing their trajectories to differ slightly. As a result, the radio frequency correction needed to stabilize the beam depends on the carbon-to-helium ratio, providing a way to measure its composition without interrupting irradiation.

The method was calculated at TU Wien and tested with MedAustron, with the results showing excellent agreement. The work was published in Physical Review Accelerators and Beams on September 25, 2026. Researchers from international particle accelerator facilities also met at TU Wien on October 8 and 9, 2026, for the 1st Workshop on Mixed Ion Beam Delivery.

“We were able to demonstrate that this method allows us to determine the helium and carbon fractions in the beam without affecting or interrupting the beam itself. This means that during experiments, and possibly also during treatments in the future, we can check whether the helium fraction in the beam corresponds to the desired value. Only if that is the case should the beam be cleared for irradiation,” said Elisabeth Renner of TU Wien.

Related Links
TU Wien


Gold Member
12-Channel ECG
CM1200B
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Rapid Sepsis Test
SeptiCyte RAPID
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.